Failure of papaverine to reduce pruritus in atopic dermatitis: a double-blind, placebo-controlled cross-over study
- 1 April 1990
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 122 (4), 553-557
- https://doi.org/10.1111/j.1365-2133.1990.tb14733.x
Abstract
Papaverine has been reported, largely on the basis of clinical experience, to reduce the severity of pruritus associated with atopic dermatitis. A double-blind, placebo-controlled, cross-over study was performed to assess the degree of improvement. Fifty subjects with atopic dermatitis each received papaverine 100 mg q.d.s. orally for 4 weeks and another 4 weeks of matching placebo in randomized order. The parameters used to measure response were pruritus as assessed on visual analogue scales by the subjects, clinical scoring of extent and severity of the dermatitis and rate of usage of topical steroid preparations. Forty-five subjects completed the protocol and no improvement in any parameter was demonstrated.Keywords
This publication has 6 references indexed in Scilit:
- Papaverine therapy in atopic dermatitisJournal of the American Academy of Dermatology, 1985
- Immunopharmacology of the Atopic DiseasesJournal of Investigative Dermatology, 1985
- Diagnostic Features of Atopic DermatitisActa Dermato-Venereologica, 1980
- The two‐period cross‐over clinical trial.British Journal of Clinical Pharmacology, 1979
- 328. Note: The Use of None-Parametric Methods in the Statistical Analysis of the Two-Period Change-Over DesignPublished by JSTOR ,1972
- Antipruritic Qualities of Papaverine Hydrochloride11Received for publication October 24, 1946.Journal of Investigative Dermatology, 1947